載入...
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Research Foundation
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://ncbi.nlm.nih.gov/pubmed/21713127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2011.00029 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|